Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The National Health Authority is developing a national artificial intelligence policy for healthcare to guide wider use of technology to address health challenges including diagnostics, public health programmes, and digital health platforms. This will be a major shift toward structured, large-scale adoption of technology in India’s health system. It can improve access, efficiency, and data-driven decision-making across public healthcare delivery.
Source: shortlink.uk/1tzfD

2. India’s Central government has directed states to uniformise package rates for common medical procedures, adopt uniform treatment guidelines, and implement digital claims processing through the National Health Claims Exchange to improve billing transparency and reduce pricing variations across private hospitals. These disparities have been identified in driving higher insurance premiums and affecting affordability.
Source: shortlink.uk/1ohsz

3. The Bombay High Court delivered a judgment after scrutinising enforcement under the Drugs (Prices Control) Order (DPCO), holding that overcharging determinations and recovery demands must strictly adhere to statutory methodology, including correct price fixation, computation, and grant of hearing. Finding procedural infirmities and inadequate reasoning, the Court set aside the demand and directed fresh adjudication, reinforcing due process and curbing arbitrary.
Source: shortlink.uk/1tzfM

4. The Central Drugs Standard Control Organization (CDSCO) has issued a regulatory communication outlining updated requirements related to drug approvals, compliance, and regulatory submissions for industry stakeholders. This is important as increased regulatory scrutiny may impact approval timelines and documentation standards. Companies may now need to review regulatory submissions, strengthen compliance processes, and align product lifecycle strategies with evolving CDSCO expectations.
Source: shortlink.uk/1tzfQ

5. The Drugs Technical Advisory Board has approved a proposal to amend the Medical Devices Rules, 2017 to introduce a definition of reportable events and mandate adverse event reporting, including for in-vitro diagnostic devices. This is important as it strengthens post-market surveillance and device safety oversight. Manufacturers and importers may now need enhanced reporting systems and tighter compliance processes.
Source: shortlink.uk/1ohsK

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. Indonesia’s health ministry has directed food companies to introduce coloured labels indicating nutritional content, within two years. Red and green labels will indicate high and low sugar, salt, and fat content respectively. Companies must revise packaging and validate nutritional content to meet the new labelling requirements, but detailed sanctions for non-compliance have not been informed yet.
Source: shortlink.uk/1nEyC

2. Gujarat Food and Drug Control Administration has reportedly directed all ayurvedic medicine manufacturers to register on the ayudmla.gujarat.gov.in portal and upload complete legacy records, mandating digital compliance for licensing processes across the state. It strengthens regulatory oversight and promotes digital compliance in the ayurvedic sector.
Source: shortlink.uk/1sU3e

3. The Bangalore District Chemists and Druggists Association and other retail pharmacy groups have urged regulators to mandate licensing requirements for e-pharmacies displaying medicines online, similar to physical stores under the Drugs and Cosmetics Act, 1940. This is important as it highlights growing concerns around patient safety, regulatory gaps, and unfair competition. If implemented, e-pharmacy platforms may face stricter compliance, licensing requirements, and potential changes to their marketplace and digital medicine distribution models.
Source: shortlink.uk/1sU3h

4. A leading weight loss drug manufacturer has partnered with OpenAI to deploy artificial intelligence across drug discovery, manufacturing, and operations, while training its workforce globally. The initiative will help to enhance productivity, strengthen competitive positioning in the obesity therapeutics market, and improve overall efficiency without immediate workforce reductions.
Source: shortlink.uk/1nEyI

5. The Bangalore District Chemists and Druggists Association and other retail pharmacy groups have urged regulators to extend licensing norms for medicine display to e-pharmacies, seeking clarity on “offer for sale” under the Drugs and Cosmetics Act. This is important to curb unlicensed digital sales and ensure parity, potentially bringing online platforms under stricter licensing and compliance requirements.
Source: shortlink.uk/1sU3l

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

1. The Supreme Court ruled that mixing samples collected from contraband contained in various packages after a seizure violates the terms of the Narcotic Substances and Psychotropic Substances Act and the rules enacted under it. The court noted that the statutory rules require a specific procedure to be followed, and the Detecting Officer is obligated to follow the authorized procedure. No one can presume the nature of the substance based on speculations and conjectures.
Source: bit.ly/3zN4yV9

2. The Central Consumer Protection Authority fined a firm selling ayurvedic oil ₹ 10 lakh for violating consumer protection laws on misleading advertisements which claimed relief from joint pain without surgery or physiotherapy while promoting their joint-pain-relieving product.
Source: bit.ly/3W1YJum

3. Following the Central Government’s decision to replace British-era criminal procedure codes with Bharatiya Sanhitas, the Government of India held a meeting with the Drugs Control Officers (India) Welfare Association (DCO India) to change the name of the Drugs and Cosmetics Act, 1940, passed by the British Rulers to ‘Bharatiya Aushadhi awam Chikitsa Upakaran Adhiniyam’. The national conference of Indian drug regulators will hold in-depth discussions on the subject.
Source: bit.ly/3WphadL

4. The National Health Authority (NHA) and the Insurance Regulatory and Development Authority of India (IRDAI) collaborated to launch the National Health Claim Exchange (NHCX), a digital platform for exchanging insurance claims-related information among healthcare and insurance stakeholders. The NHCX will enable seamless interoperability of health claims processing, allowing citizens to track their insurance claim progress via mobile devices.
Source: bit.ly/3xQ9EPX

5. The US Food and Drug Administration (FDA) issued final question-and-answer guidance outlining how it assesses user fees for combination products, as well as the various programs available to sponsors for requesting user fee waivers under the Prescription Drug User Fee Act (PDUFA) and Medical Device User Fee Amendments (MDUFA). The guideline offers background information on combination goods, how the agency calculates user fees for single and multiple applications, and how to request waivers or reductions in user costs.
Source: bit.ly/3y3roHw